|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
On examination of DNA from dewaxed sections of the tumor, we found no p53 mutation in the tumor tissue, but found two K-ras mutations in codon 12; this pattern of mutation commonly occurs in pancreatic carcinoma, indicating a somewhat genetic relationship of OGTP to pancreatic carcinoma.
|
9779494 |
1998 |
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We analyzed the inactivation of p53 in the human pancreas cancer cell line Hs766T, which harbors a structural alteration in the p53 gene.
|
9850060 |
1998 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated p53 gene transfer suppressed growth of all human pancreatic cancer cell lines in a dose-dependent manner.
|
9869513 |
1998 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study confirms that loss of chromosomes, particularly chromosomes 17 and 18, which carry the p53 and DCC genes, are common in pancreas cancer.Chromosome 20 is also frequently lost.
|
10090407 |
1999 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The p16(INK4a) (MTS-1, CDKN2) gene product acts in the same pathway as p53 to inhibit cell cycle progression at G1/S. p16(INK4a) is deleted and/or mutated in a significant fraction of human tumors, including pancreatic carcinoma.
|
10210535 |
1999 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The mutational pattern of p53 in pancreatic cancer is similar to bladder cancer, another smoking-related cancer, but not to lung cancer.
|
10217065 |
1999 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Therefore, simultaneous analysis of p53 and K-ras mutation is suggested to enhance the genetic diagnosis of pancreatic cancer.
|
10353750 |
1999 |
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Therefore, it is concluded that simultaneously aberrant expression of Bcl-2 and p53 may confer PC with more malignant clinicopathological characteristics.
|
10362119 |
1999 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
From these, K-ras mutations detected in blood, stool and bile juice of patients at risk for pancreatic cancer seem to be more promising than p53 alterations as a more later step in carcinogenesis, although they are neither yet well established nor standardised by reliable assays.
|
10436809 |
1999 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Studies have demonstrated that pancreatic cancer is associated with various genetic abnormalities in oncogenes and tumor suppressor genes including p53.
|
10680837 |
2000 |
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In addition, it seems that cooperation of Ki-ras PM and p53 expression may predict a poor prognosis in Chinese patients with pancreatic cancer.
|
10750666 |
2000 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using a novel improved primer extension and preamplification polymerase chain reaction, we analyzed microdissected paraffin-embedded specimens of pancreatic carcinoma (n = 29) and their corresponding pancreatic intraductal lesions (PIL, n = 331) for loss of heterozygosity (LOH) of p16(INK4), DPC4, and p53 by microsatellite analysis and for p53 protein by immunohistochemistry.
|
10880379 |
2000 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A molecular examination of Ki-ras codon 12 and p53 mutations therefore enables us to predict, to some degree, the occurrence of liver and lymph node metastasis in pancreatic carcinoma.
|
10950039 |
2000 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TP53 and BRCA2 germline mutations seem not to be significantly associated with the occurrence of multiple primaries in pancreatic cancer patients.
|
11075991 |
2000 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
|
11097231 |
2000 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results show that transfer of wild-type p53 and p16 produces significant growth suppression of pancreatic cancer in vitro and in vivo.
|
11313791 |
2001 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer.
|
11332152 |
2001 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in p53 and ras genes are frequent in pancreatic carcinoma.
|
11375580 |
2001 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The mutation profiles of p53 and K-ras genes in pancreatic cancer resemble that in bladder cancer rather than that in lung cancer.
|
11561602 |
2002 |
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Pancreatic cancer is particularly resistant to apoptosis by antineoplastic agents, which is partly attributable to the lack of functional p53.
|
11585734 |
2001 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2.
|
11694525 |
2002 |
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that overexpression of p21(WAF1/CIP1) occurs early in the development of PanIN, before aberrations in p53, cyclin D1, and DPC4/Smad4 expression. p21(WAF1/CIP1) overexpression, independent of p53 and/or DPC4/Smad4 expression, may reflect increased Ras activity, either directly through activating K-ras mutations or as a consequence of HER-2/neu (ERBB2) overexpression, both of which are common in PC and in early events in the development of PanIN.
|
11751405 |
2001 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activation of the proto-oncogene K-Ras and inactivation of the tumour suppressor gene loci INK4a, p53 and SMAD4 are characteristic for pancreatic cancer.
|
12079267 |
2002 |
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
|
12171884 |
2002 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of the current study was conducted to investigate the association between p53 mutation and VEGF expression and the prognostic value of these factors in pancreatic carcinoma.
|
12298426 |
2002 |